2014
For “a prolific biostatistician and devoted educator, [who] has contributed immensely to his field and inspired countless students at the Medical College of Virginia and other universities to achieve greatness in science and medicine.

Commendation from the Virginia General Assembly

2014
For Improving Public Health through academic and laboratory advancement

GPHA Sellers-McCroan Award Recipient

Special Presidential Award for Service: International Chinese Statistical Association

Delta Omega chapter Karl E. Peace Leadership Award

Regent’s Hall of Fame Alumni Award

Tito Mijares Life Time Achievement Award Recipient

2008-2009
Excellence In Research And/Or Creative Scholarly Activity
Georgia Southern University

Academic Year 2008-2009 Award Recipient

2008
The Resolution Recognizes Karl E. Peace For His Contributions To The Medical Field, To The Jiann-Ping Hsu College Of Public Health, To Georgia Southern University, And To The Citizens Of The State Of Georgia

Georgia House Of Representatives Passed House Resolution #2118

2008
Georgia General Assembly Recognizes Dr. Karl E. Peace As A Distinguished Georgian

Georgia House Resolution HR #2118

2007
For Contributions To The Pharmaceutical Industry, Biostatistics & Public Health, American Public Health Association

APHA Statistics Section Award

The President’s Medal For Outstanding And Meritorious Contributions To Georgia Southern University

Number Needed to Treat in Multiple Sclerosis Clinical Trials

A Serious Flaw in Nutrition Epidemiology: A Meta-Analysis Study.

A comparison of size and power of tests of hypotheses on parameters based on two generalized Lindley distributions

Size and power of tests of hypotheses on survival parameters from the Lindley distribution with covariates

A SASR Algorithm For Imputing Discrete Missing Outcomes Based On Minimum Distance

Joint Modeling Of Treatment Effect On Time-To-Event Endpoint And Safety Covariates In Control Clinical Trial Data Analysis

Analysis Of Subgroup Data Of Clinical Trials

Approximating The Baseline Hazard Function By Taylor Series For Interval-Censored Time-To-Event Data

Spline Nonparametric Quasi-Likelihood Regression Within The Frame Of The Accelerated Failure Time Model

Genetic Matching: A Better Algorithm For Adjusting Covariate Imbalance For Statistical Data Analysis And Modeling

Interval-Censored Time-to-Event Data: Methods and Applications collects the most recent techniques, models, and computational tools for interval-censored time-to-event data. Top biostatisticians from academia, biopharmaceutical industries, and government agencies discuss how these advances are impacting clinical trials and biomedical research.  Divided into three parts, the book begins with an overview of interval-censored data modeling, including nonparametric estimation, survival functions, regression analysis, multivariate data analysis, competing risks analysis, and other models for interval-censored data. The next part presents interval-censored methods for current status data, Bayesian semiparametric regression analysis of interval-censored data with monotone splines, Bayesian inferential models for interval-censored data, an estimator for identifying causal effect of treatment, and consistent variance estimation for interval-censored data. In the final part, the contributors use Monte Carlo simulation to assess biases in progression-free survival analysis as well as correct bias in interval-censored time-to-event applications. They also present adaptive decision making methods to optimize the rapid treatment of stroke, explore practical issues in using weighted logrank tests, and describe how to use two R packages.  A practical guide for biomedical researchers, clinicians, biostatisticians, and graduate students in biostatistics, this volume covers the latest developments in the analysis and modeling of interval-censored time-to-event data. It shows how up-to-date statistical methods are used in biopharmaceutical and public health applications.

Interval-Censored Time-to-Event Data: Methods and Applications (Chapman &amp; Hall/CRC Biostatistics Series)

In biostatistical research and courses, practitioners and students often lack a thorough understanding of how to apply statistical methods to synthesize biomedical and clinical trial data. Filling this knowledge gap, Applied Meta-Analysis with R shows how to implement statistical meta-analysis methods to real data using R.   Drawing on their extensive research and teaching experiences, the authors provide detailed, step-by-step explanations of the implementation of meta-analysis methods using R. Each chapter gives examples of real studies compiled from the literature. After presenting the data and necessary background for understanding the applications, various methods for analyzing meta-data are introduced. The authors then develop analysis code using the appropriate R packages and functions. This systematic approach helps readers thoroughly understand the analysis methods and R implementation, enabling them to use R and the methods to analyze their own meta-data.  Suitable as a graduate-level text for a meta-data analysis course, the book is also a valuable reference for practitioners and biostatisticians (even those with little or no experience in using R) in public health, medical research, governmental agencies, and the pharmaceutical industry.

Applied Meta-Analysis with R (Chapman &amp; Hall/CRC Biostatistics Series)

Review of the First Edition "The goal of this book, as stated by the authors, is to fill the knowledge gap that exists between developed statistical methods and the applications of these methods. Overall, this book achieves the goal successfully and does a nice job. I would highly recommend it …The example-based approach is easy to follow and makes the book a very helpful desktop reference for many biostatistics methods."―Journal of Statistical Software  Clinical Trial Data Analysis Using R and SAS, Second Edition provides a thorough presentation of biostatistical analyses of clinical trial data with step-by-step implementations using R and SAS. The book’s practical, detailed approach draws on the authors’ 30 years’ experience in biostatistical research and clinical development. The authors develop step-by-step analysis code using appropriate R packages and functions and SAS PROCS, which enables readers to gain an understanding of the analysis methods and R and SAS implementation so that they can use these two popular software packages to analyze their own clinical trial data.  What’s New in the Second Edition   Adds SAS programs along with the R programs for clinical trial data analysis.   Updates all the statistical analysis with updated R packages.   Includes correlated data analysis with multivariate analysis of variance.   Applies R and SAS to clinical trial data from hypertension, duodenal ulcer, beta blockers, familial andenomatous polyposis, and breast cancer trials.   Covers the biostatistical aspects of various clinical trials, including treatment comparisons, time-to-event endpoints, longitudinal clinical trials, and bioequivalence trials. 

Clinical Trial Data Analysis Using R and SAS (Chapman &amp; Hall/CRC Biostatistics Series)

Using time-to-event analysis methodology requires careful definition of the event, censored observation, provision of adequate follow-up, number of events, and independence or "noninformativeness" of the censoring mechanisms relative to the event. Design and Analysis of Clinical Trials with Time-to-Event Endpoints provides a thorough presentation of the design, monitoring, analysis, and interpretation of clinical trials in which time-to-event is of critical interest.  After reviewing time-to-event endpoint methodology, clinical trial issues, and the design and monitoring of clinical trials, the book focuses on inferential analysis methods, including parametric, semiparametric, categorical, and Bayesian methods; an alternative to the Cox model for small samples; and estimation and testing for change in hazard. It then presents descriptive and graphical methods useful in the analysis of time-to-event endpoints. The next several chapters explore a variety of clinical trials, from analgesic, antibiotic, and antiviral trials to cardiovascular and cancer prevention, prostate cancer, astrocytoma brain tumor, and chronic myelogonous leukemia trials. The book then covers areas of drug development, medical practice, and safety assessment. It concludes with the design and analysis of clinical trials of animals required by the FDA for new drug applications.  Drawing on the expert contributors’ experiences working in biomedical research and clinical drug development, this comprehensive resource covers an array of time-to-event methods and explores an assortment of real-world applications.

Design and Analysis of Clinical Trials with Time-to-Event Endpoints (Chapman &amp; Hall/CRC Biostatistics Series)

Now viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial. Drawing from the authors’ courses on the subject as well as the first author’s more than 30 years working in the pharmaceutical industry, Clinical Trial Methodology emphasizes the importance of statistical thinking in clinical research and presents the methodology as a key component of clinical research. From ethical issues and sample size considerations to adaptive design procedures and statistical analysis, the book first covers the methodology that spans every clinical trial regardless of the area of application. Crucial to the generic drug industry, bioequivalence clinical trials are then discussed. The authors describe a parallel bioequivalence clinical trial of six formulations incorporating group sequential procedures that permit sample size re-estimation. The final chapters incorporate real-world case studies of clinical trials from the authors’ own experiences. These examples include a landmark Phase III clinical trial involving the treatment of duodenal ulcers and Phase III clinical trials that contributed to the first drug approved for the treatment of Alzheimer’s disease.Aided by the U.S. FDA, the U.S. National Institutes of Health, the pharmaceutical industry, and academia, the area of clinical trial methodology has evolved over the last six decades into a scientific discipline. This guide explores the processes essential for developing and conducting a quality clinical trial protocol and providing quality data collection, biostatistical analyses, and a clinical study report, all while maintaining the highest standards of ethics and excellence. 

Clinical Trial Methodology (Chapman &amp; Hall/CRC Biostatistics Series Book 35)

Georgia Southern University is the state’s largest and most comprehensive center of higher education south of Atlanta. With 142 degree programs at the bachelor’s, master’s and doctoral levels, Georgia Southern has been designated a Carnegie Doctoral/Research university and serves more than 27,000 students from all 50 states, Washington D.C., and Puerto Rico as well as 102 nations. With three vibrant campuses — the Armstrong Campus in Savannah, the Statesboro Campus and the Liberty Campus in Hinesville — Georgia Southern offers an attractive campus environment that encourages learning, discovery and personal growth. Georgia Southern’s nationally accredited academic programs prepare diverse scholars for leadership and service as world citizens. A unit of the University System of Georgia, the University boasts 200-plus student organizations, outstanding Division I athletics, and state-of-the art residence halls and campus facilities.

Since 1906, the University’s hallmark has been a culture of engagement that bridges theory with practice, extends the learning environment beyond the classroom, and promotes student growth and life success. Central to the University’s mission is the faculty’s dedication to excellence in teaching and the development of a fertile learning environment exemplified by a free exchange of ideas, high academic expectations, and individual responsibility for academic achievement. Faculty, staff, and students embrace core values expressed through integrity, civility, kindness, collaboration, and a commitment to lifelong learning, wellness, and social responsibility.

Georgia Southern University

Dr. Peace began a career in biostatistics in the pharmaceutical industry in 1978. After rising from an entry-level biostatistician position at Burroughs-Wellcome to vice president of worldwide technical operations at Parke-Davis/Warner Lambert, he started Biopharmaceutical Research Consultants Inc. in 1989. Dozens of international biotech and pharmaceutical companies relied on his expertise and he played a key role in the development and regulatory approval of dozens of medicines, including drugs used to treat Alzheimer’s disease, hypertension, arthritis, anxiety, depression and panic attacks, and gastrointestinal ulcers. At the same time, Peace kept one foot in the classroom, serving as an adjunct faculty member at Duke University, the MCV, the University of Michigan, The University of North Carolina, Temple University, and Virginia Commonwealth University. Peace approached Georgia Southern University officials in 1998 with a plan to establish a biostatistics center at the university, a corresponding program of study in biostatistics at the graduate level, and a school of public health. He returned to the Statesboro, Georgia, campus in the fall of 2000, when Georgia Southern began to offer the masters of public health degree in biostatistics that he and Charles Hardy developed. In 2004, his endowment to honor his late wife led to the creation of the Jiann-Ping Hsu College of Public Health (JPHCOPH), the first college or school of public health in the University System of Georgia (USG). In creating the JPHCOPH, the board of regents also named the center for biostatistics the Karl E. Peace Center for Biostatistics. He is author, co-author or editor of 15 books, 22 book chapters and over 100 articles in the scientific, medical or biostatistical literature; and is the recipient of over 50 prestigious awards. He has donated much of his time, talent and treasure to create opportunities for others, particularly our youth, to improve their lots and selves.

Clinical Trials

Pharmaceutical Research

Health & Disease

Health Sciences

Biostatistics

Clinical Development

Faculty Profile

Professional Page

ResearchGate

PlumX Profile

online-with-an-upside-find-out-how-georgia-southern-is-making-education-accessible-from-anywhere-in-a-field-with-societal-benefits

Professor, Georgia Cancer Coalition Distinguished Cancer Scholar, Jiann-Ping College of Public Health

Beginning in Fall 2020 Georgia Southern University will offer its first fully online Master of Public Health (MPH) degree with a concentration in applied public health.  “For those who do not have the ability to enroll in one of our on-campus MPH concentrations, the online applied public health option would be ideal for anyone passionate about improving health and making a difference in their community,” stated Interim Dean Stuart Tedders, Ph.D. Students will complete a broad-based program of study with a focus on public health education, information and advocacy, and with the flexibility to tailor their elective options. Students will apply their skills and knowledge to become front-line public health practitioners or public health leaders.  Academic advisors and technical support will be provided to all students enrolled in the online master’s program. Additionally, the online program includes a field experience located within reach of the student’s location.   Are you a journalist looking to cover this topic or learn more about Georgia Southern University and the programs it offers? Simply contact Melanie Simón at 912.344.2904 to arrange an interview or contact Karl Peace via his icon directly. 

Select Inquiry Type